Skip to main content
Premium Trial:

Request an Annual Quote

Aaron Shatkin, Kevin Farr, Richard Ulevitch, and David Hoffmeister

Premium

Serologicals said last week that Aaron Shatkin has been elected to the company’s board of directors.

Shatkin is currently the director of the Center for Advanced Biotechnology and Medicine, as well as a professor of molecular genetics and microbiology at the Robert W. Johnson Medical School in Piscataway, NJ. He is also a professor of molecular biology at Rutgers University. Shatkin is a member of the National Academy of Sciences and the American Academy of Arts and Sciences, and has been a member of the board of directors of Upstate since the company’s inception, Serologicals said. Serologicals completed its acquisition of Upstate last week (see News Scan in this issue for more).


Beckman Coulter last week announced that Kevin Farr, chief financial officer for Mattel, has been elected to its board of directors, effective Oct. 8. Farr holds an MBA from Northwestern University’s J L Kellogg Graduate School of Business. He received his bachelor’s degree from Michigan State University. The addition of Farr to Beckman Coulter’s board raises the number of company directors from 10 to 11. Farr will stand for election at the next annual stockholder meeting in April, the company said.


MultiCell has named Richard Ulevitch to its scientific advisory board, the company said last week.

Ulevitch is currently chairman of the department of immunology at The Scripps Research Institute in La Jolla, Calif. He received a PhD in biochemistry from the University of Pennsylvania, and completed a postdoc at the University of Minnesota.


David Hoffmeister has become CFO and senior vice president of Invitrogen, succeeding Eric Winzer, the Carlsbad, Calif.-based company said last week. He joins Invitrogen from McKinsey, where he was a senior partner. Winzer will remain part of the Invitrogen executive team, the company said.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.